Alexion Pharmaceuticals to Present Data on Soliris(R) (Eculizumab) and PNH at the 2007 American Society of Hematology (ASH) Annu...( CHESHIRE Conn. Dec. 7 /- AlexionP...),Health

CHESHIRE, Conn., Dec. 7 /PRNewswire-FirstCall/ -- Alexion Pharmaceuticals, Inc. (Nasdaq: ALXN) today announced that data relating to paroxysmal nocturnal hemoglobinuria (PNH), as well as to Soliris(R) (eculizumab), a treatment for patients with PNH, will be presented at the 2007 American Society of Hematology Meeting, December 8 - 11 in Atlanta.

The following abstracts will be presented in a poster session on red cell regulation and disorders of production on Monday, December 10, 2007. The session will open at 10:30 a.m. and poster presentations will be held from 5:00 to 7:00 p.m. for each abstract. Additional information can be accessed through the links provided below.

-- Poster # 897-III: "High Incidence of Progression to Chronic Renal

Insufficiency in Patients with Paroxysmal Nocturnal Hemoglobinuria

(PNH)" Dr. Peter Hillmen et al.

-- Location: Hall B3 and B4

-- http://www.abstracts2view.com/hem07/view.php?nu=HEM07L1_5416

-- Poster # 891-III: "Sustained Improvements in Transfusion

Requirements, Fatigue and Thrombosis with Eculizumab Treatment in

Paroxysmal Nocturnal Hemoglobinuria" Dr. Gerard Socie et al.

-- Location: Hall B3 and B4

-- http://www.abstracts2view.com/hem07/view.php?nu=HEM07L1_5204

-- Poster # 902-III: "Disease-Related Symptoms Reported across a Broad

Population of Patients with Paroxysmal Nocturnal Hemoglobinuria" Dr.

Gabrielle Meyers et al.

-- Location: H
'/>"/>